Novo Nordisk will lose Canadian patent rights for a major medication due to the failure to pay a minor fee.

China, known for its low obesity rates, emerges as a center for weight loss medication research - STAT News

AbbVie's Venetoclax for Cancer Fails to Meet Expectations in Phase 3 Combination Study - Benzinga

US pharmaceutical companies invest heavily in China to acquire promising blockbuster medications - Pharmacy Business

China's Biotechnology Surge Indicates Worldwide Aspirations - CBBC Focus